Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Syn - The Untold Story

Synagistics and Mei Entertainment Launch AI-powered Ecommerce Brand MASYN

HONG KONG, June 11, 2026 /PRNewswire/ -- Synagie, the digital commerce arm of Synagistics Limited ("Synagistics", Stock Code: 2562.HK), and Mei Ah Entertainment Group ("Mei Ah Entertainment"), today announced a strategic partnership to launch MASYN, a new AI-powered ecommerce project that combines AI content creation, data validation and cross-border ecommerce…

AAP · Jun 11

Castelli Premio Evo Jersey Review: Premio name, premium price

Castelli's Premio Evo Jersey aims to offer premium comfort and performance by using innovative fabrics

Cycling Weekly · Jun 8

'Tech product campaigns fall short when it comes to emotion': How we made Life Fitness's Symbio branding

We caught up with the team at marketing agency Syn.

Creative Bloq · Aug 4, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

"Covid was really the making of us": A day in the life of syn co-founder Chris Newell

How the "horrible time" of Covid ended up shaping Leeds agency syn.

Creative Bloq · May 2, 2024

The best rebrands of 2020s (so far)

From nostalgic revisions to bold new campaigns – these are the best rebrands of the decade, as picked by industry experts.

Creative Bloq · Apr 23, 2024

Much-loved community radio station saved from closure

Youth community radio station SYN has been saved from imminent closure following a mammoth fundraising effort and a funding injection from the state government.

AAP · Nov 21, 2023

Push to keep much-loved community radio station alive

A Melbourne community radio station with several high-profile alumni is facing the prospect of shutting for good, prompting a plea for donations.

AAP · Oct 5, 2023

Read news from The Economist, FT, and more,
with one subscription

Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers

Synthetic Biologics Inc (NYSE:SYN) has announced safety data from its Phase 1 multiple ascending dose (MAD) trial of SYN-020 intestinal alkaline phosphatase (IAP). The Phase 1 MAD study enrolled 32 healthy adult volunteers into four cohorts with SYN-020 administered orally in doses ranging from 5 mg to 75 mg twice daily for 14…

Benzinga · May 10, 2022

Synthetic Biologics' VCN-01 Shows Favorable Safety Profile, Clinical Activity In Early-Stage Cancer Study

Synthetic Biologics Inc (NYSE: SYN)

Benzinga · Mar 29, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.